Veritas Bio said this week that the European Patent Office has granted the company a patent covering its nucleic acid-delivery technology.
The patent, granted on patent application No. 07873598.21401, is entitled "In Vivo Delivery of Nucleic Acids," and covers the transfection of nucleic acids into skin or muscle cells. A US patent application on the technology was recently issued a notice of allowance.
As reported by Gene Silencing News, Vertias was established by the co-founders of defunct expressed RNAi drug firm Nucleonics as a holding company for the delivery technology while they look for parties interested in licensing the intellectual property (GSN 4/18/2013).